Clinicians face numerous challenges incorporating advances in hepatocellular carcinoma (HCC) treatment into practice. Revised EASL guidelines highlight personalized surveillance based on risk assessment, standardized imaging procedures, and minimally invasive surgery for complex cases. They emphasize the critical role of liver transplantation, therapeutic transitions, and the integration of immunotherapy at different disease stages. A multidisciplinary team approach is essential for evaluating individual risks and benefits to improve patient outcomes in HCC management.
Practice Guideline by None None; None None in J Hepatol
Copyright © 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.